Insider filing
Traded Nov 16 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 4, 2026 · Filed Nov 4, 2026
Arcutis Biotherapeutics's Chief Legal Officer sold $1.37M of Arcutis Biotherapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$1,372,672
Shares × reported transaction price
on the day of results (Nov 4, 2026)
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $34.05 on Nov 4, 2026, at its 52-week high, after a 29% rise over the previous 30 trading days
52-week range $19.50 (May 19, 2026) to $34.05 (Nov 4, 2026), 100% of the way up, from 250 adjusted closes. 30 trading days earlier: $26.38 on Sep 23, 2026. Describes the past only, not a forecast
RSI 70, 34% above its 200-day average, 25% above its 50-day average, at the 52-week high, 20-day volatility 63% a year, against the S&P 500: +44 points over 1 month, +26 points over 3 months, +39 points over 6 months
From the adjusted closes up to Nov 4, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
Masaru Matsuda's largest sale of ARQT in their filings since 2022
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.0% | +3.3% | −1.3% |
Past results only. Not a forecast.
Insider filing
Traded Nov 16 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Howard G. Welgus (Director) sold ~$133K of Arcutis Biotherapeutics
Planned saleInsider filing
Traded Nov 16 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.